Obagi Clear Fx: the brightening product, price and review display

The current Obagi page names Clear Fx Skin Brightening Cream. Although its address ends with “serum,” the visible description is a cream with nature-identical arbutin and antioxidants. A word embedded in a URL should not replace the product name and description when identifying what a source discusses. Clear Fx record

Its published ingredient list begins with water and arbutin and includes other components such as glycerin, ascorbic acid and sodium metabisulfite. It does not state an arbutin percentage in the reviewed text or identify hydroquinone in that list. This is a website record, not an assay or an inspection of a particular package.

Obagi’s separate Nu-Derm Clear prescription page identifies hydroquinone 4%, a listed inactive formulation and professional access. Those details do not describe the Fx product merely because the names overlap. A prescription-product warning or a hydroquinone treatment study must not be silently attached to an arbutin cream. Clear prescription page

The active-name comparison explains why hydroquinone, arbutin and kojic acid cannot become one interchangeable label. This also works in the other direction: a retail price or favorable Fx review does not establish a Clear Rx quote, response or tolerability. Each statement should stay with the record that actually supports it.

The product page displays a $125 regular price. Its direct HTML also presents a one-time purchase option and a subscription promotion described as 15% off the current and recurring orders, subject to change. Delivery choices of one, two, three or four months appear in that subscription control. Those are commercial delivery options, not instructions for using the cream. Current purchase options

We did not select an option or verify an order total. The page contains several purchase, notification and inventory-related template elements, which are insufficient to establish whether a specific order can currently be fulfilled. A displayed price is therefore not a stock confirmation or a tested charge.

The same page advertises free shipping on orders of $165 or more, with exclusions for Alaska, Puerto Rico, Hawaii and APO/FPO addresses. Its free thirty-day-return statement is a headline on the product page. We have not checked an individual order’s eligibility or treated that headline as proof that every opened or used product would qualify. Retail offer details

Those conditions belong to this product’s retail context. They are not the terms of prescription Clear Rx or a CoreAge plan. The pricing-conflict article shows another way a comparison can go wrong: collapsing distinct price statements into a convenient but unverified total.

The page labels its review summary as generated by AI from a selected set of recent customer reviews. That summary is a new presentation of customer reports, not a clinical study or this publication’s independent account of their experiences. We did not inspect purchase records, contact reviewers or verify the skin concerns and other products involved. Obagi review presentation

FTC’s health-products guidance explains that genuine anecdotes still do not establish causation or substantiate an implied health benefit. The testimonial guide explores that distinction without pronouncing individual reviews true or false. A readable summary can make reports easier to scan while leaving the same evidence limitations in place. FTC guidance

Obagi presents Clear Fx as an appearance-focused retail cream. FDA explains that intended use is central to the distinction between cosmetics and drugs, including claims made online. A cosmetic-style presentation therefore should not become a legal conclusion made by this review. FDA also notes the color-additive exception when explaining that cosmetics generally do not require premarket approval. FDA category framework

Neither retail availability nor a “dermatologist tested” claim establishes approval or the result of a particular clinical study. The product page includes its own AHA-related sunburn warning. We preserve the existence of that warning without turning it into an application routine or assuming the product is risk-free. Product precautions

AAD’s melasma guidance describes professional assessment because discoloration can have different explanations. A retail brightening claim does not determine which one applies to a reader. It also cannot decide whether appearance-focused care, medical evaluation or another discussion is the appropriate next step for a particular person. AAD context

The product-label questions keep the exact name and source version visible when asking for clarification. Our Spot On review applies the same method to the promoted compound. Clear Fx’s own records are sufficiently specific to discuss; they do not need borrowed prescription evidence or an invented clinical rating to make that discussion useful.